Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The ...

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx ...

Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $160 from $153 and keeps an Overweight rating on the shares. The firm notes ...

Principal Financial Group Inc. lessened its stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and ...

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...

Fintel reports that on February 19, 2025, Mizuho upgraded their outlook for Glaukos (NYSE:GKOS) from Neutral to Outperform.

Rhumbline Advisers lifted its holdings in Glaukos Co. (NYSE:GKOS – Free Report) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The ...

Glaukos (GKOS) delivered earnings and revenue surprises of 6.98% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

ALISO VIEJO, Calif. (AP) — ALISO VIEJO, Calif. (AP) — Glaukos Corp. (GKOS) on Thursday reported a loss of $33.6 million in its fourth quarter. On a per-share basis, the Aliso Viejo, California-based ...